Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences - 1 Nov 2004

Antila Saila, Pesonen Ullamari, Lehtonen Lasse, Tapanainen Pasi, Nikkanen Hanna, Vaahtera Katja, Scheinin Harry

Abstract excerpt

OBJECTIVE: The purpose of this study was to investigate the pharmacokinetics of levosimendan and to determine the primary pharmacokinetic parameters of the pharmacologically active metabolite OR-1896 in rapid and slow acetylators. METHODS: Levosimendan was administered as a constant rate (0.1 microg/(kg min)) i.v. infusion for 24h in six rapid and six slow acetylators based on N-acetyltransferase 2 genotyping. At...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Arylamine N-Acetyltransferase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Blood Proteins

Share to Carbon Radioisotopes

Share to Cardiotonic Agents

Share to Half-Life

Share to Infusions, Intravenous

Share to Pyridazines

Source

Identifiers

PMID: 15489122
DOI: 10.1016/j.ejps.2004.07.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators.PMID 15489122Read ↗

Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.Semantic proximity Read ↗

Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine β-hydroxylase inhibitor, in healthy subjects.Semantic proximity Read ↗

N-acetylation phenotyping with sulphadimidine in a Turkish population.Semantic proximity Read ↗

Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.Semantic proximity Read ↗

Pharmacokinetics, acetylation-deacetylation, renal clearance, and protein binding of sulphamerazine, N4-acetylsulphamerazine, and N4-trideuteroacetylsulphamerazine in 'fast' and 'slow' acetylators.Semantic proximity Read ↗

Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.Semantic proximity Read ↗

Predominance of slow acetylators of N-acetyltransferase in a Hmong population residing in the United States.Semantic proximity Read ↗

Mesalazine pharmacokinetics and NAT2 phenotype.Semantic proximity Read ↗

Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.Semantic proximity Read ↗

Pharmacokinetic studies of sulfapyridine acetylation in the rabbit.Semantic proximity Read ↗

Amantadine acetylation may be effected by acetyltransferases other than NAT1 or NAT2.Semantic proximity Read ↗

Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.